{"id":48716,"date":"2025-11-20T16:52:06","date_gmt":"2025-11-20T08:52:06","guid":{"rendered":"https:\/\/flcube.com\/?p=48716"},"modified":"2025-11-20T16:52:07","modified_gmt":"2025-11-20T08:52:07","slug":"freenome-roche-cancer-screening-deal-worth-over-200m","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48716","title":{"rendered":"Freenome Roche Cancer Screening Deal Worth Over $200M"},"content":{"rendered":"\n

Freenome<\/strong>, a California\u2011based early cancer detection company, announced a strategic collaboration with Roche<\/strong> (SWX: ROG<\/a>, OTCMKTS: RHHBY<\/a>) to commercialize its blood\u2011based screening technology in international markets, featuring a $75\u202fmillion equity investment and total deal value exceeding USD\u202f200\u202fmillion<\/strong>.<\/p>\n\n\n\n

Deal Structure<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Partners<\/strong><\/td>Freenome (U.S.) and Roche (Switzerland)<\/td><\/tr>
Equity Investment<\/strong><\/td>$75\u202fmillion by Roche in Freenome<\/td><\/tr>
Total Potential Value<\/strong><\/td>>$200\u202fmillion (including milestones)<\/td><\/tr>
Geographic Rights<\/strong><\/td>Roche: Exclusive ex\u2011U.S. rights for “kitted” tests; Freenome: Retains U.S. rights and centralized testing rights outside U.S.<\/td><\/tr>
Technology Focus<\/strong><\/td>Cell\u2011free DNA (cfDNA) based cancer screening tests<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Technology & Collaboration Scope<\/h2>\n\n\n\n